Senescence-associated secretory phenotype regulation by dual drug delivery biomimetic nanoplatform for enhanced tumor chemotherapy

Many chemotherapies, which are still the main clinical treatment for primary tumors, will induce persistent DNA damage in non-tumor stromal cells, especially cancer-associated fibroblasts (CAFs), and activate them to secrete senescence-associated secretory phenotype (SASP). The transition could furt...

Full description

Saved in:
Bibliographic Details
Main Authors: Anni Wang, Shiyi Li, Ru Zhang, Xing Chen, Ying Zhu, Jiaxuan Xia, Jianxin Wang
Format: Article
Language:English
Published: Elsevier 2024-09-01
Series:Molecular Therapy: Oncology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2950329924000985
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1846159042646376448
author Anni Wang
Shiyi Li
Ru Zhang
Xing Chen
Ying Zhu
Jiaxuan Xia
Jianxin Wang
author_facet Anni Wang
Shiyi Li
Ru Zhang
Xing Chen
Ying Zhu
Jiaxuan Xia
Jianxin Wang
author_sort Anni Wang
collection DOAJ
description Many chemotherapies, which are still the main clinical treatment for primary tumors, will induce persistent DNA damage in non-tumor stromal cells, especially cancer-associated fibroblasts (CAFs), and activate them to secrete senescence-associated secretory phenotype (SASP). The transition could further result in the formation of tumor immunosuppressive microenvironment and cause drug resistance of neighboring tumor cells. To solve this dilemma, a multi-functional biomimetic drug delivery system (named mPtP@Lipo) was rationally developed by combining CAFs reshaper ginsenoside 20(S)-protopanaxadiol (PPD) and cisplatin prodrug (PtLA) to inhibit tumor progression and the formation of SASP. To achieve effective delivery of these molecules deep into the desmoplastic tumor, fibroblast membrane was fused with liposomes as a targeting carrier. In vitro and in vivo results showed that mPtP@Lipo could penetrate deep into the tumor, reverse CAFs phenotype and inhibit SASP formation, which then blocked the immunosuppressive progress and thus reinforced anti-tumor immune response. The combination of chemotherapeutics and CAFs regulator could achieve both tumor inhibition and tumor immune microenvironment remodeling. In conclusion, mPtP@Lipo provides a promising strategy for the comprehensive stromal-desmoplastic tumor treatment.
format Article
id doaj-art-946ceffd9932460d96d0a69e6824f967
institution Kabale University
issn 2950-3299
language English
publishDate 2024-09-01
publisher Elsevier
record_format Article
series Molecular Therapy: Oncology
spelling doaj-art-946ceffd9932460d96d0a69e6824f9672024-11-24T04:15:46ZengElsevierMolecular Therapy: Oncology2950-32992024-09-01323200856Senescence-associated secretory phenotype regulation by dual drug delivery biomimetic nanoplatform for enhanced tumor chemotherapyAnni Wang0Shiyi Li1Ru Zhang2Xing Chen3Ying Zhu4Jiaxuan Xia5Jianxin Wang6Department of Pharmaceutics, School of Pharmacy, Fudan University and Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Fudan University and Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Fudan University and Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Fudan University and Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Fudan University and Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China; Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, ChinaDepartment of Pharmaceutics, School of Pharmacy, Fudan University and Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, ChinaDepartment of Pharmaceutics, School of Pharmacy, Fudan University and Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China; Corresponding author: Jianxin Wang, Department of Pharmaceutics, School of Pharmacy, Fudan University and Key Laboratory of Smart Drug Delivery, Ministry of Education, Shanghai 201203, China.Many chemotherapies, which are still the main clinical treatment for primary tumors, will induce persistent DNA damage in non-tumor stromal cells, especially cancer-associated fibroblasts (CAFs), and activate them to secrete senescence-associated secretory phenotype (SASP). The transition could further result in the formation of tumor immunosuppressive microenvironment and cause drug resistance of neighboring tumor cells. To solve this dilemma, a multi-functional biomimetic drug delivery system (named mPtP@Lipo) was rationally developed by combining CAFs reshaper ginsenoside 20(S)-protopanaxadiol (PPD) and cisplatin prodrug (PtLA) to inhibit tumor progression and the formation of SASP. To achieve effective delivery of these molecules deep into the desmoplastic tumor, fibroblast membrane was fused with liposomes as a targeting carrier. In vitro and in vivo results showed that mPtP@Lipo could penetrate deep into the tumor, reverse CAFs phenotype and inhibit SASP formation, which then blocked the immunosuppressive progress and thus reinforced anti-tumor immune response. The combination of chemotherapeutics and CAFs regulator could achieve both tumor inhibition and tumor immune microenvironment remodeling. In conclusion, mPtP@Lipo provides a promising strategy for the comprehensive stromal-desmoplastic tumor treatment.http://www.sciencedirect.com/science/article/pii/S2950329924000985MT: Regular Issuecancer-associated fibroblastschemotherapyliposomessenescence-associated secretory phenotypetumor microenvironment
spellingShingle Anni Wang
Shiyi Li
Ru Zhang
Xing Chen
Ying Zhu
Jiaxuan Xia
Jianxin Wang
Senescence-associated secretory phenotype regulation by dual drug delivery biomimetic nanoplatform for enhanced tumor chemotherapy
Molecular Therapy: Oncology
MT: Regular Issue
cancer-associated fibroblasts
chemotherapy
liposomes
senescence-associated secretory phenotype
tumor microenvironment
title Senescence-associated secretory phenotype regulation by dual drug delivery biomimetic nanoplatform for enhanced tumor chemotherapy
title_full Senescence-associated secretory phenotype regulation by dual drug delivery biomimetic nanoplatform for enhanced tumor chemotherapy
title_fullStr Senescence-associated secretory phenotype regulation by dual drug delivery biomimetic nanoplatform for enhanced tumor chemotherapy
title_full_unstemmed Senescence-associated secretory phenotype regulation by dual drug delivery biomimetic nanoplatform for enhanced tumor chemotherapy
title_short Senescence-associated secretory phenotype regulation by dual drug delivery biomimetic nanoplatform for enhanced tumor chemotherapy
title_sort senescence associated secretory phenotype regulation by dual drug delivery biomimetic nanoplatform for enhanced tumor chemotherapy
topic MT: Regular Issue
cancer-associated fibroblasts
chemotherapy
liposomes
senescence-associated secretory phenotype
tumor microenvironment
url http://www.sciencedirect.com/science/article/pii/S2950329924000985
work_keys_str_mv AT anniwang senescenceassociatedsecretoryphenotyperegulationbydualdrugdeliverybiomimeticnanoplatformforenhancedtumorchemotherapy
AT shiyili senescenceassociatedsecretoryphenotyperegulationbydualdrugdeliverybiomimeticnanoplatformforenhancedtumorchemotherapy
AT ruzhang senescenceassociatedsecretoryphenotyperegulationbydualdrugdeliverybiomimeticnanoplatformforenhancedtumorchemotherapy
AT xingchen senescenceassociatedsecretoryphenotyperegulationbydualdrugdeliverybiomimeticnanoplatformforenhancedtumorchemotherapy
AT yingzhu senescenceassociatedsecretoryphenotyperegulationbydualdrugdeliverybiomimeticnanoplatformforenhancedtumorchemotherapy
AT jiaxuanxia senescenceassociatedsecretoryphenotyperegulationbydualdrugdeliverybiomimeticnanoplatformforenhancedtumorchemotherapy
AT jianxinwang senescenceassociatedsecretoryphenotyperegulationbydualdrugdeliverybiomimeticnanoplatformforenhancedtumorchemotherapy